Filters close
Released: 15-Dec-2017 8:30 AM EST
Results of Clinical Testing in Retinitis Pigmentosa
jCyte

In a phase 1/2a study jCyte's investigational therapy, jCell, showed a good safety profile and indications of potential benefit for patients with retinitis pigmentosa

Released: 2-May-2017 8:00 AM EDT
jCyte Receives Regenerative Medicine Advanced Therapy Designation
jCyte

Cell therapy company jCyte has received Regenerative Medicine Advanced Therapy designation from the FDA for their developmental retinitis pigmentosa therapy.

Released: 19-Apr-2017 7:00 AM EDT
Powered by CIRM Grant, jCyte Launches New Clinical Trial
jCyte

Cell-based therapy company jCyte is launching a Phase 2b clinical trial to study the effectiveness of its developmental therapy for retinitis pigmentosa.

Released: 28-Nov-2016 10:00 AM EST
jCyte Completes Enrollment for Phase I/IIa Safety Trial
jCyte

Regenerative medicine company jCyte has completed enrollment in a phase I/IIa trial studying the safety of its stem cell therapy for retinitis pigmentosa. Early results are promising.

Released: 14-Jul-2016 5:05 PM EDT
Early Trial Results Support the Safety of Cell-Based Retinitis Pigmentosa Treatment
jCyte

Regenerative medicine company jCyte and the Sue & Bill Gross Stem Cell Research Center at the University of California, Irvine report that their investigational therapy for retinitis pigmentosa (RP) has demonstrated a favorable safety and tolerability profile in an ongoing Phase I/II clinical trial.



close
0.0769